Iqvia doesn’t have some blockbuster drug or cutting-edge genetic treatment. It is a data company that collects prescription sales, medical claims and other patient records, and analyzes that information for drugmakers, insurance companies and governments. It also provides testing services to drug companies.
Last year, the Durham, N.C., company paid its CEO, Ari Bousbib, $38 million. J&J, the largest U.S. pharmaceutical company by revenue, paid its CEO, Alex Gorsky, $29.8 million in 2017. J&J had about $76 billion in revenue in 2017, Iqvia’s was about $8 billion.
The two companies delivered similar shareholder gains last year. J&J’s stock-price appreciation plus dividends returned 24.4% to investors, while the smaller company returned 28.7%.
Mr. Bousbib’s 2017 pay included a one-time retention equity award valued at about $20 million following an October 2016 merger between IMS Health, a data company where he was CEO, and Quintiles, which assisted pharmaceutical companies with clinical trials. The combined company was then renamed Iqvia.
“The special one-time retention equity grant vests over four years and was awarded to recognize the special circumstances around the appointment of our CEO as the CEO of the new company that resulted from the merger,” an Iqvia spokesman said. Much of the CEO’s compensation is tied to the company’s performance, he said.
Mr. Bousbib, 56 years old, joined IMS Health in 2010 after spending 14 years in executive roles at industrial conglomerate United Technologies Inc. In 2015, IMS increased his pay to more than $34 million from about $25 million. The company said in its 2015 regulatory filings that Mr. Bousbib might be an attractive job candidate for other companies, which contributed to his increased compensation along with his performance as CEO.
The median CEO pay for 25 pharmaceutical, biotechnology and life-science executives in the S&P 500 was $16.08 million, above the overall median of $12.1 million for CEOs at all S&P 500 companies, according to a Wall Street Journal analysis of pay data from MyLogIQ LLC. Median overall shareholder returns for companies in these medical sectors were about 22% compared with 19% overall, according to performance data from ISS Analytics. The Journal analysis used Standard & Poor’s industry group for pharmaceutical, biotechnology and life sciences companies, which includes data providers like Iqvia as well as instrument suppliers such as Mettler-Toledo International Inc.
The Journal’s analysis excludes CEOs who changed jobs or served less than a full year. See the full list of pharmaceutical and biotech CEOs here:
Corrections & Amplifications
An Iqvia Holdings Inc. spokesman said the company’s CEO had received a one-time equity grant linked to an earlier merger. An earlier version of this article incorrectly attributed the comment to a company spokeswoman. (June 12, 2018)
A Product Manager with expertise in pharma marketing and sales operations